ARTICLE | Product Development
GSK to provide adjuvant to boost effectiveness, stretch supplies of 2019-nCoV vaccines
February 3, 2020 4:41 AM UTC
Updated on Mar 26, 2020 at 1:06 AM UTC
GlaxoSmithKline will provide its AS03 adjuvant technology to enhance 2019-nCoV vaccines that are being funded by the Coalition for Epidemic Preparedness Innovations, GSK and CEPI announced Sunday.
AS03 has been used in GSK’s H1N1 and H5N1 pandemic influenza vaccines...